The FDA is expected to make decisions about therapies for small-cell lung cancer and myelodysplastic syndrome next month. The US Food and Drug Administration (FDA) is expected to decide in June ...
Tarlatamab is an investigational first-in-class, bispecific T-cell engager immunotherapy designed to target delta-like ligand 3 on small cell lung cancer (SCLC) cells and CD3 on T cells. The ...